Table 1 Studies included in the analysis
Study | Duration (weeks) | No. in ITT (PR) populations | Main eligibility criteria | COPD medication allowed during the study | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Salmeterol | Placebo | Definition | Age (yrs) | FEV1 (% predicted % absolute value) | FEV1/FVC | OCS | ICS | Antichol. | MX |
van Noord | 12 | 49 (40) | 50 (44) | ATS | 40–75 | ≤65% & ≥ 0.75L | ≤60% | Yes | ≤ 1 mg/day FP* | No | Yes |
Rennard | 12 | 131 (84) | 133 (85) | ATS | ≥35 | ≤ 65% & > 0.7L or ≥ 40% & <0.7L | ≤70% | ≤ 10 mg prednisolone* | Yes | No | No |
Mahler | 12 | 135 (78) | 143 (90) | ATS | ≥35 | ≤65% & >0.7L or ≥ 40% & <0.7L | ≤70% | ≤10 mg prednisolone* | Yes | No | No |
Boyd | 16 | 228 (221) | 227 (215) | ERS | 40–75 | ≤70% & >0.6L | ≤60% | Yes | Yes | Yes | Yes |
Mahler | 24 | 164 (105) | 185 (130) | ATS | ≥40 | <65% & >0.7L or >40% & ≤0.7L | ≤70% | No | No | No | Yes |
Hanania | 24 | 176 (112) | 185 (118) | ATS | ≥40 | <65% & > 0.7L or >40% & ≤0.7L | ≤70% | No | No | No | Yes |
Chapman | 24 | 201 (173) | 206 (171) | ERS | ≥40 | ≤85% | ≤70% | Yes | Yes | Yes | Yes |
Calverley | 52 | 372 (371) | 361 (359) | ERS | 40–79 | ≥25%–≤70% | ≤70% | Exacerbations | No | Yes | Yes |
Stockley | 52 | 316 (292) | 318 (304) | ERS | ≥40 | <70% | Not stated | Exacerbations | ≤1 mg/day FP* | Yes | Yes |
Pooled | 1772 (1476) | 1808 (1516) | Â | Â | Â | Â | Â | Â | Â | Â | |